Ahmed Bakhit
Interventional Cardiology · Flint, MINPI 1780920777
Payments from drug & device makers
What this record shows
This record is dominated by grants: $50,000 of the $61,433 with a category attached, or 81.4%. Boston Scientific accounts for 81.6% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2024 at $53,266 and has fallen 95.3% since, to $2,492 in 2025.
Across 315 payments — averaging $195.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$50K
- Abbott$4K
- Amgen$807
- E.r. Squibb & Sons, L.L.C.$718
- Novartis$564
- Medtronic$547
- plus $5K from 28 others
What the payments were for
- Grants$50,00081%
- Travel & lodging$2,3634%
- Food & beverage$8,62414%
- Education$4461%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 4 | $50,099 |
| Abbott | 37 | $4,171 |
| Amgen | 28 | $807 |
| E.r. Squibb & Sons, L.L.C. | 35 | $718 |
| Novartis | 26 | $564 |
| Medtronic(2 entities) | 17 | $547 |
| AstraZeneca | 19 | $532 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $446 |
| Boehringer Ingelheim | 21 | $437 |
| Pfizer | 20 | $415 |
| Johnson & Johnson | 16 | $407 |
| Teleflex LLC | 3 | $270 |
| Asahi Intecc USA, Inc. | 5 | $231 |
| Abiomed | 4 | $219 |
| Bayer | 4 | $202 |
| Merck | 9 | $164 |
| Sanofi-aventis U.S. LLC | 7 | $163 |
| Penumbra, Inc. | 1 | $142 |
| Amarin Pharma, Inc. | 6 | $113 |
| Lexicon Pharmaceuticals, Inc. | 5 | $111 |
| Kiniksa Pharmaceuticals, Ltd. | 5 | $93 |
| Alnylam Pharmaceuticals Inc. | 3 | $72 |
| Novo Nordisk | 3 | $68 |
| Vifor Pharma, Inc. | 3 | $63 |
| Regeneron Healthcare Solutions, Inc. | 3 | $63 |
| Heartflow, Inc. | 2 | $59 |
| Lantheus Medical Imaging, Inc. | 2 | $45 |
| Z-medica, LLC | 2 | $44 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $41 |
| Edwards Lifesciences | 1 | $33 |
| Altathera Pharmaceuticals LLC | 2 | $31 |
| Actelion Pharmaceuticals US, Inc. | 1 | $30 |
| GSK | 1 | $20 |
| Astellas Pharma US Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PERCLOSE PROGLIDE$1,734
- OPTIS$1,159
- Repatha$225
- PERIPHERAL VASCULAR$214
- MANTA$146
- Resolute$144
- Indigo System$142
- Impella$141
- MitraClip$115
How this compares
$61,433 in reported general payments places this provider in the 85th percentile of 187 interventional cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 93 | $96,495 |
| EntrestoSacubitril/Valsartan | 80 | $72,808 |
| XareltoRivaroxaban | 32 | $34,176 |
| FarxigaDapagliflozin Propanediol | 30 | $30,643 |
| BrilintaTicagrelor | 24 | $27,026 |
| Repatha SureclickEvolocumab | 21 | $19,116 |
| Rosuvastatin Calcium | 93 | $3,124 |
| Metoprolol Succinate | 172 | $3,068 |
| Atorvastatin Calcium | 149 | $2,678 |
| Ezetimibe | 58 | $2,166 |
| Carvedilol | 70 | $1,084 |
| Losartan Potassium | 50 | $613 |
| ClopidogrelClopidogrel Bisulfate | 46 | $582 |
| Lisinopril | 57 | $580 |
| Metoprolol Tartrate | 43 | $362 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $415 | $96,49593 claims |
| NovartisEntresto | $564 | $72,80880 claims |
| AstraZenecaFarxiga, Brilinta | $532 | $57,67054 claims |
| Johnson & JohnsonXarelto | $407 | $34,17632 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 187 interventional cardiology providers in Michigan.
Other interventional cardiology in Flint
- Ahmad MunirFlint$176K
- Ali Akram KhanFlint$23K
- Amir KakiDetroit$1.8M
- Tamam MohamadDetroit$960K
- Paul GrossmanAnn Arbor$630K
- Jason RicciPetoskey$594K
- Tim FischellKalamazoo$468K
- Mir BasirDetroit$442K
- Amr AbbasBerkley$416K
- Safwan KassasSaginaw$340K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.